Ligand price target raised to $155 from $143 at RBC Capital

RBC Capital raised the firm’s price target on Ligand (LGND) to $155 from $143 and keeps an Outperform rating on the shares. The firm cites the company’s better than expected Q4 results while the management reaffirmed 2025 revenue and core EPS guidance and anticipates multiple value-creating milestones in 2025, including a potential strategic transaction and subsequent launch of Zelsuvmi by mid-2025, the analyst tells investors in a research note.